Importantly, a higher CRP level was associated with shorter OS in ccRCC and nccRCC, suggesting the prognostic value of serum CRP for the first-line ipilimumab and nivolumab in mRCC including nccRCC. Here, CRP is linked to nonpapillary renal cell carcinoma.